Refining metformin prescribing in New Zealand.
N Z Med J
; 130(1452): 49-53, 2017 Mar 24.
Article
em En
| MEDLINE
| ID: mdl-28337040
ABSTRACT
Metformin is the mainstay of treatment of type 2 diabetes. However, there has been significant concern on prescribing metformin in patients with renal impairment as a result of metformin-associated lactic acidosis (MALA). Recent studies have cast doubt on the existence of MALA purely related to metformin use. Medsafe recently initiated changes to datasheet so lower doses of metformin could be used in patients with GFR down to 15ml/min. In this paper we outline the context and implications of this change.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Acidose Láctica
/
Diabetes Mellitus Tipo 2
/
Insuficiência Renal Crônica
/
Taxa de Filtração Glomerular
/
Hipoglicemiantes
/
Metformina
Limite:
Humans
País/Região como assunto:
Oceania
Idioma:
En
Revista:
N Z Med J
Ano de publicação:
2017
Tipo de documento:
Article